Impressive Numbers That Matter: Abiomed Inc (ABMD)
Post# of 90
Posted On: 01/27/2015 11:54:25 PM
Keep a close eye on ABIOMED, Inc. (ABMD). The company delivered a robust performance on its financial results that demonstrates the growing clinical need for percutaneous heart pumps that improve patient care and enable minimally invasive procedures.
For the third quarter fiscal 2015, ABMD posted record revenue of $62.0 million, a 34% increase year over year, and GAAP net income of $12.7 million, or $0.30 per diluted share, compared to $4.4 million, or $0.11 per diluted share, in the same period the prior year
ABMD has raised its fiscal year 2015 guidance for total revenue to the range of $223 million to $226 million (which represents an increase of 21% to 23% versus fiscal 2014) from its previous range of $209 million to $212 million (which represented an increase of 14% to 15% from the prior year)
ABMD also said that the Impella RP(R) (Right Percutaneous) System has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first percutaneous single access heart pump designed for right heart support to receive FDA approval.
Delivered through a catheter requiring only a small hole in the leg, the Impella RP is FDA indicated for providing circulatory assistance for up to 14 days in pediatric or adult patients who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. These patients lack blood flow from the right side of their hearts. ABMD's Impella RP is designed to provide the flow and pressure needed to compensate for right heart failure. The device does not require a surgical procedure for insertion, and it provides up to four liters per minute of hemodynamic support.
Fiscal 2015 third quarter worldwide Impella(R) revenue totaled $57.4 million, an increase of 37% compared to revenue of $42.0 million during the same period of the prior year.
ABMD is a leading provider of medical devices that provide circulatory support. Its products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
More about ABIOMED, Inc. (ABMD) at www.abiomed.com
**
Freescale Semiconductor, Ltd. (FSL) reported a solid performance on its financial results that shows the company continues to make consistent progress in gaining market share, improving profitability and improving its capital structure
For the fourth quarter 2014, FSL posted net sales of $1.10 billion, a 2% increase year over year, and net earnings of $63 million, or $0.20 per share, compared to a net loss of $118 million, or a loss per share of ($0.46), in the fourth quarter 2013. Net earnings for the period included the impact of $12 million of reorganization of business and other charges and $10 million of costs related to FSL’s redemption of $100 million of debt securities during the fourth quarter.
For the full year 2014, FSL posted net sales of $4.63 billion, an 11% increase year over year, and net earnings of 251 million, or $0.83 per share, compared to a net loss of $208 million, or a loss per share of ($0.81) in the full year 2013
For the first quarter 2015, FSL expects net sales to be between $1.135 billion and $1.185 billion.
FSL is a global leader in embedded processing solutions, providing industry leading products that are advancing the automotive, consumer, industrial and networking markets. From microprocessors and microcontrollers to sensors, analog integrated circuits and connectivity – FSL's technologies are the foundation for the innovations that make our world greener, safer, healthier and more connected.
More about Freescale Semiconductor, Ltd. (FSL) at www.freescale.com
**
Apple Inc. (AAPL) reported record quarterly revenue and net profit on its financial results, fueled by all-time record revenue from iPhone(R) and Mac(R) sales as well as record performance of the App Store(SM)
For its first quarter fiscal 2015, AAPL posted revenue of $74.6 billion, compared to $57.6 billion in the same period the prior year, and net profit of $18 billion, or $3.06 per diluted share, versus net profit of $13.1 billion, or $2.07 per diluted share in the first quarter fiscal 2014
For its second quarter fiscal 2015, AAPL expects revenue to be in the range of $52 billion to $55 billion.
AAPL designs Macs, the best personal computers in the world, along with OS X, iLife, iWork and professional software. AAPL leads the digital music revolution with its iPods and iTunes online store. AAPL has reinvented the mobile phone with its revolutionary iPhone and App Store, and is defining the future of mobile media and computing devices with iPad
More about Apple Inc. (AAPL) at www.apple.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Orange, CA ( www.orange.crwe-pr.com ) into the CRWE Network.
The City of Orange is located in Central Orange County, approximately 32 miles southeast of Los Angeles, California. It is home to one of the strongest retail and automotive markets in the southland. Orange has captured the regional crown as the antique capital of Southern California with its acclaimed Old Towne historical district.
The City of Orange had an estimated population in 2013 (U.S. Census Bureau) of 139,969, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
For the third quarter fiscal 2015, ABMD posted record revenue of $62.0 million, a 34% increase year over year, and GAAP net income of $12.7 million, or $0.30 per diluted share, compared to $4.4 million, or $0.11 per diluted share, in the same period the prior year
ABMD has raised its fiscal year 2015 guidance for total revenue to the range of $223 million to $226 million (which represents an increase of 21% to 23% versus fiscal 2014) from its previous range of $209 million to $212 million (which represented an increase of 14% to 15% from the prior year)
ABMD also said that the Impella RP(R) (Right Percutaneous) System has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first percutaneous single access heart pump designed for right heart support to receive FDA approval.
Delivered through a catheter requiring only a small hole in the leg, the Impella RP is FDA indicated for providing circulatory assistance for up to 14 days in pediatric or adult patients who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. These patients lack blood flow from the right side of their hearts. ABMD's Impella RP is designed to provide the flow and pressure needed to compensate for right heart failure. The device does not require a surgical procedure for insertion, and it provides up to four liters per minute of hemodynamic support.
Fiscal 2015 third quarter worldwide Impella(R) revenue totaled $57.4 million, an increase of 37% compared to revenue of $42.0 million during the same period of the prior year.
ABMD is a leading provider of medical devices that provide circulatory support. Its products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
More about ABIOMED, Inc. (ABMD) at www.abiomed.com
**
Freescale Semiconductor, Ltd. (FSL) reported a solid performance on its financial results that shows the company continues to make consistent progress in gaining market share, improving profitability and improving its capital structure
For the fourth quarter 2014, FSL posted net sales of $1.10 billion, a 2% increase year over year, and net earnings of $63 million, or $0.20 per share, compared to a net loss of $118 million, or a loss per share of ($0.46), in the fourth quarter 2013. Net earnings for the period included the impact of $12 million of reorganization of business and other charges and $10 million of costs related to FSL’s redemption of $100 million of debt securities during the fourth quarter.
For the full year 2014, FSL posted net sales of $4.63 billion, an 11% increase year over year, and net earnings of 251 million, or $0.83 per share, compared to a net loss of $208 million, or a loss per share of ($0.81) in the full year 2013
For the first quarter 2015, FSL expects net sales to be between $1.135 billion and $1.185 billion.
FSL is a global leader in embedded processing solutions, providing industry leading products that are advancing the automotive, consumer, industrial and networking markets. From microprocessors and microcontrollers to sensors, analog integrated circuits and connectivity – FSL's technologies are the foundation for the innovations that make our world greener, safer, healthier and more connected.
More about Freescale Semiconductor, Ltd. (FSL) at www.freescale.com
**
Apple Inc. (AAPL) reported record quarterly revenue and net profit on its financial results, fueled by all-time record revenue from iPhone(R) and Mac(R) sales as well as record performance of the App Store(SM)
For its first quarter fiscal 2015, AAPL posted revenue of $74.6 billion, compared to $57.6 billion in the same period the prior year, and net profit of $18 billion, or $3.06 per diluted share, versus net profit of $13.1 billion, or $2.07 per diluted share in the first quarter fiscal 2014
For its second quarter fiscal 2015, AAPL expects revenue to be in the range of $52 billion to $55 billion.
AAPL designs Macs, the best personal computers in the world, along with OS X, iLife, iWork and professional software. AAPL leads the digital music revolution with its iPods and iTunes online store. AAPL has reinvented the mobile phone with its revolutionary iPhone and App Store, and is defining the future of mobile media and computing devices with iPad
More about Apple Inc. (AAPL) at www.apple.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Orange, CA ( www.orange.crwe-pr.com ) into the CRWE Network.
The City of Orange is located in Central Orange County, approximately 32 miles southeast of Los Angeles, California. It is home to one of the strongest retail and automotive markets in the southland. Orange has captured the regional crown as the antique capital of Southern California with its acclaimed Old Towne historical district.
The City of Orange had an estimated population in 2013 (U.S. Census Bureau) of 139,969, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)Abiomed (ABMD) Stock Research Links
Scroll down for more posts ▼